These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27659016)

  • 1. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
    Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
    Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
    Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
    Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
    Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
    Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
    Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
    J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
    Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
    Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
    López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
    Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions.
    Tella SH; Taïeb D; Pacak K
    Eur J Cancer; 2017 Nov; 86():1-4. PubMed ID: 28946040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.
    Taïeb D; Barlier A; Yang C; Pertuit M; Tchoghandjian A; Rochette C; Zattara-Canoni H; Figarella-Branger D; Zhuang Z; Pacak K; Metellus P
    J Neurooncol; 2016 Feb; 126(3):473-81. PubMed ID: 26514359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia and paraganglioma with a novel somatic HIF2A mutation in a male.
    Toyoda H; Hirayama J; Sugimoto Y; Uchida K; Ohishi K; Hirayama M; Komada Y
    Pediatrics; 2014 Jun; 133(6):e1787-91. PubMed ID: 24819565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
    Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
    Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
    Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma.
    Eckardt L; Prange-Barczynska M; Hodson EJ; Fielding JW; Cheng X; Lima JDCC; Kurlekar S; Douglas G; Ratcliffe PJ; Bishop T
    Endocr Relat Cancer; 2021 Oct; 28(12):757-772. PubMed ID: 34658364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas.
    Yang C; Sun MG; Matro J; Huynh TT; Rahimpour S; Prchal JT; Lechan R; Lonser R; Pacak K; Zhuang Z
    Blood; 2013 Mar; 121(13):2563-6. PubMed ID: 23361906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.
    Bernardo-Castiñeira C; Valdés N; Sierra MI; Sáenz-de-Santa-María I; Bayón GF; Perez RF; Fernández AF; Fraga MF; Astudillo A; Menéndez R; Fernández B; Del Olmo M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2018 Jan; 103(1):295-305. PubMed ID: 29126304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas.
    Merlo A; de Quiros SB; Secades P; Zambrano I; Balbín M; Astudillo A; Scola B; Arístegui M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2012 Nov; 97(11):E2194-200. PubMed ID: 22977270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
    Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new twist in neuroendocrine tumor research: Pacak-Zhuang syndrome, HIF-2α as the major player in its pathogenesis and future therapeutic options.
    Jochmanova I; Lazurova I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):175-80. PubMed ID: 24781045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.
    Span PN; Rao JU; Oude Ophuis SB; Lenders JW; Sweep FC; Wesseling P; Kusters B; van Nederveen FH; de Krijger RR; Hermus AR; Timmers HJ
    Endocr Relat Cancer; 2011 Jun; 18(3):323-31. PubMed ID: 21422080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
    Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.